AstraZeneca, Scorpion Therapeutics Enter Agreement for Oncology Treatments
13 January 2022 - 06:57PM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Thursday that it has signed a collaboration
agreement with Scorpion Therapeutics for the development and
commercialization of treatments for hard-to-target cancer proteins
in oncology.
The pharmaceutical giant said Scorpion will receive an upfront
cash payment of $75 million, and retain the potential for
additional success-based payments and tiered royalties on net
sales.
The partnership will focus on transcription-factors proteins and
combine Scorpion's discovery platform with AstraZeneca's
development and commercialization capabilities in precision
medicines for cancer treatment.
Transcription-factors proteins control gene expression and can
regulate cellular processes such as cell growth and survival, it
said. Many have been identified as important targets for new cancer
treatments and as disease drivers, but drug treatment was
previously considered as not possible using conventional drug
discovery approaches, it added.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 13, 2022 02:42 ET (07:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024